MELBOURNE, Australia and OXFORD, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy. The FDA’s Fast Track program facilitates the expedited development and review of new drugs or biologics that are intended

Broadens CREATE's delivery toolkit with access to Monash's novel LNP chemistries and next-generation targeting technologies. Enables rapid evaluation of diverse binder formats and cell-targeting strategies, accelerating development across multiple immune cell types and therapeutic programs. July 31, 2026 -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced a strategic research collaboration with Australia's Monash Un

Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell lung cancer (NSCLC). This means the selective ROS1 kinase inhibitor is now indicated for use in American adults with locally advanced or metastatic ROS1-positive NSCLC, provided they have already previously received treatment with a prior ROS1 kinase inhibitor. This is GSK’s first drug for lung ca

Aug. 3, 2026 -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, today announced initiation of patient dosing in a clinical study evaluating AHB-171, the Company's investigational hepatocyte-targeted small interfering RNA ( siRNA) therapeutic candidate for chronic hepatitis B. The milestone marks

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 Aug. 03, 2026 -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus pro

Aug. 02, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for an open-label, multicenter Phase Ib/II clinical trial of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination therapy for metastatic colorectal cancer (mCRC). The study is designed to

RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fibrotic efficacy July 31, 2026 -- Ractigen Therapeutics, a pioneer and global leader in small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its

July 31, 2026 -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co-founder's team presented two new studies on solid tumor cell therapy. The first, CAR-Mix™ multicellular synergistic therapy, combines engineered macrophages with polyclonal T cells and has demonstrated synergistic antitumor activity

Repatha is the Only PCSK9 Inhibitor Proven to Significantly Reduce Risk of First Heart Attack and Stroke in Phase 3 Clinical Trial, Setting a New Benchmark in Cardiovascular Risk Reduction Recommendation Based on the Landmark Phase 3 Global VESALIUS-Cardiovascular Trial of More Than 12,000 Patients July 29, 2026 -- Amgen (NASDAQ: AMGN) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Repatha® (evo

Aug. 3, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C. Olomorasib was